Duopharma Biotech Bhd
KLSE:DPHARMA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.13
1.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches MYR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Duopharma Biotech Bhd
Cash & Cash Equivalents
Duopharma Biotech Bhd
Cash & Cash Equivalents Peer Comparison
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
D
|
Duopharma Biotech Bhd
KLSE:DPHARMA
|
Cash & Cash Equivalents
myr221.2m
|
CAGR 3-Years
27%
|
CAGR 5-Years
23%
|
CAGR 10-Years
42%
|
|
P
|
PeterLabs Holdings Bhd
KLSE:PLABS
|
Cash & Cash Equivalents
myr17.5m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
18%
|
CAGR 10-Years
21%
|
|
A
|
Apex Healthcare Bhd
KLSE:AHEALTH
|
Cash & Cash Equivalents
myr86.9m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
6%
|
|
R
|
Rhone Ma Holdings Bhd
KLSE:RHONEMA
|
Cash & Cash Equivalents
myr31.9m
|
CAGR 3-Years
9%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
Y
|
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
|
Cash & Cash Equivalents
myr139.2m
|
CAGR 3-Years
6%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
K
|
Kotra Industries Bhd
KLSE:KOTRA
|
Cash & Cash Equivalents
myr4.8m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-10%
|
See Also
What is Duopharma Biotech Bhd's Cash & Cash Equivalents?
Cash & Cash Equivalents
221.2m
MYR
Based on the financial report for Jun 30, 2024, Duopharma Biotech Bhd's Cash & Cash Equivalents amounts to 221.2m MYR.
What is Duopharma Biotech Bhd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
42%
Over the last year, the Cash & Cash Equivalents growth was 63%. The average annual Cash & Cash Equivalents growth rates for Duopharma Biotech Bhd have been 27% over the past three years , 23% over the past five years , and 42% over the past ten years .
You don't have any saved screeners yet
